

Financial Statements for the 3rd quarter of fiscal year ending March 31, 2016 (From Apr. 1, 2015 to Dec. 31, 2015)

Summary of consolidated results

JMS Co., Ltd.

Company Code No. 7702

February 5, 2016

Highlights in Business Results



(unit: JPY million)

	Results Apr Dec. 2014	Results Apr Dec. 2015	Diff.	Year– over – Year
Sales	41,046	43,095	2,048	5.0%
Operating Income	401	1,019	617	154.0%
Ordinary Income	493	959	466	94.5%
Profit attributable to owners of parent	294	721	426	144.7%
Net Income per share	JPY 6.05	JPY 14.81		

Exchange Rate (average during	US Dollar	106.87	121.70	
	period)	Euro	139.54	134.77
	(unit: JPY) Sir	ngapore Dollar	84.35	88.20


Increased in sales (6th straight year) and profit for the 3rd Quarter of FYE Mar. 2016

Sales	Japan	-Launch of blood bags with leukocyte reduction filter -Increased sales of cardiopulmonary equipment
les	Overseas	-Continued growth in the sales of apheresis kits -Strong sales of AV fistula needles


Profi

- -Increase of gross profit due to a sales increase
- -Reduction of manufacturing costs as well as favorable foreign exchange conditions

Sales by segment (geographical area)



Profit by segment (geographical area)



Summary by segment (geographical area)

-%





Sales	30,811 JPY mil.	2.4%

Ordinary Ioss (9) JPY mil.

-Increased sales of cardiopulmonary equipment as well as launch of blood bags with leukocyte reduction filter raised net sales

-The higher import cost with weak yen as well as the loss of abandonment of inventories resulted in a loss



Southeast Asia

Sales 15,522 JPY mil.	13.3%
-----------------------	-------

Ordinary Income 672 IPY mil **-%**

-Continued growth in the sales of apheresis kits for North America raised net sales



Sales	3,062 JPY mil.	6.9%
Ordinary loss	(109) JPY mil.	-%

-Despite the sales drop of AV fistula needles for the domestic market, increase of yen equivalent by weak yen raised net sales

(%: year-over-year)



Blood bags with leukocyte reduction filter

It is a blood bag used for blood storage and blood transfusion collected by blood donation. It has a filter to reduce leukocyte which is one of the reasons that cause side effects after blood transfusion.

Summary by segment (geographical area)





Sales	2,410 JPY mil.	(2.3%)
-------	----------------	--------

Ordinary Income 222 JPY mil. (19.4%)

-Increased sales of dialysis therapy chairs for Australian market was offset by decrease of sales in yen equivalent by strong yen, reducing net sales

United States

Sales	2,4/3 JPY mil.	16.4%
Ordinary Income	102 JPY mil.	25.2%

-Strong sales of AV fistula needles for Latin American market raised net sales



Sales	1,426 JPY mil.	7.9%
Ordinary loss	(230) JPY mil.	- %

Others

(%: year-over-year)




AV Fistula Needle


AV fistula needle is for pulling blood from a patient during a dialysis therapy.

Sales by Business Segment





Sales by Segment (Customer's Location)






Selling, General and Admin. Expenses




(unit: JPY million)



(unit: JPY million)


	Apr Dec. 2014	Apr Dec. 2015	Diff.	Year -over- Year
Labor Cost	4,215	4,349	133	3.2%
Transport	1,299	1,234	(65)	(5.0%)
R & D	844	868	23	2.8%
Depreciation	320	309	(10)	(3.4%)
Others	3,046	3,300	254	8.4%
Total	9,726	10,062	335	3.5%

Ordinary Income: Compared with the previous year



Ordinary income increased
JPY 466 million

Ordinary Income Apr.-Dec. 2015



The underlined figures exclude impact of exchange rate.

Forecast for FYE Mar. 2016



(unit: JPY million)

	FYE Mar. 2015 Result	FYE M	ar. 2016 Forecast	
		Previous Forecast	New Forecast	Amount Changed
Sales	55,401	58,000	58,000	-%
Operating Income	378	700	1,100	57.1%
Ordinary Income	373	800	1,100	37.5%
Profit attributable to owners of parent	139	500	800	60.0%
Net Income per share	JPY 2.85	JPY 10.26	JYP 16.41	

(unit: JPY)

Exchange Rate (average during period)

US Dollar	109.93	115.00	120.72	
Euro	140.42	125.00	134.31	
Singapore Dollar	85.21	92.00	86.73	

Consolidated business forecast for the fiscal year ending March 31, 2016 has been revised, due to the above mentioned business results.





The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.